Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Efficacité et convivialité de l'exosquelette EXPLORER chez les enfants atteints de troubles neurodéveloppementaux en milieu naturel

13 novembre 2026 mis à jour par: MarsiBionics

Efficacité et convivialité de l'exosquelette EXPLORER chez les enfants atteints de troubles neurodéveloppementaux dans leur environnement naturel

Neurodevelopmental disorders often lead to abnormal development of the Central Nervous System (CNS), frequently causing motor dysfunctions such as an inability to stand and walk. EXPLORER is a robotic gait exoskeleton designed to rehabilitate children with motor disabilities in home and outdoor environments.

The aim of this study is to evaluate the efficacy and usability of EXPLORER in children with motor disability within their natural settings, including home and community environments.

Aperçu de l'étude

Statut

Complété

Intervention / Traitement

Description détaillée

Neurodevelopmental disorders often lead to abnormal development of the Central Nervous System (CNS), frequently causing motor dysfunctions such as an inability to stand and walk. Robotic devices are a useful tool in the rehabilitation of these children, but most of them are designed to be used in the clinical setting. EXPLORER is a robotic device designed to assist gait in children with motor disability in their homes and the community. The aim of this study is to evaluate the efficacy and usability of EXPLORER in children with motor disability within their natural settings, including home and community environments.

An initial session will be conducted in the participant's natural environment, during which the researchers will instruct the primary caregivers on the use of the device. Subsequently, the device will be left for a two-month period for use in the natural settings deemed appropriate by the family.

Type d'étude

Interventionnel

Inscription (Réel)

20

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Madrid
      • Alcorcón, Madrid, Espagne, 28922
        • Universidad Rey Juan Carlos
      • Madrid, Madrid, Espagne, 28046
        • Hospital Universitario La Paz
      • Madrid, Madrid, Espagne, 28009
        • Hospital Infantil Universitario Niño Jesús-Servicio de Neuro Ortopedia
      • Madrid, Madrid, Espagne, 28007
        • Hospital Universitario Gregorio Marañón
      • Madrid, Madrid, Espagne, 28009
        • Hospital Infantil Universitario Niño Jesús - Servicio de Rehabilitación
      • Madrid, Madrid, Espagne, 28041
        • Hospital Universitario 12 Octubre

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

2 ans à 17 ans (Enfant)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Diagnosis of any pathology or condition causing neurodevelopmental disorders.
  • Ability to continuously use the device for two weeks, at least 3 times per week, without causing excessive fatigue that would prevent the participant from carrying out their usual activities.
  • Availability and commitment from the family to use the device at least 3 times per week during the planned period, in different environments and with various objectives.
  • Medical authorization for standing, gait training and weight bearing.
  • Informed consent signed by legal guardians.
  • Maximum user weight of 60 kg.
  • Hip width (between greater trochanters) ≤37 cm.
  • Length of the thigh (distance from the greater trochanter to the lateral condyle of the tibia) from 21cm to 36cm.
  • Tibia leg length (distance from the lateral condyle of the tibia to the lateral malleolus) from 20cm to 35cm.
  • Shoe size ≤40 (EU)

Exclusion Criteria:

  • Medical contraindications for standing or walking.
  • Non-reducible contractures or heterotropic ossifications above the degrees allowed by the device or out of the trajectory imposed by the device
  • Spasticity equal to 4 on the Modified Ashworth Scale at the time of use of the device.
  • More than 20º of hip and/or knee non-reducible contractures at the time of using the exoskeleton.
  • Necessity to walk with more than 5º of hip abduction.
  • Impossibility to reach 5º of ankle dorsiflexion with ir without orthoses.
  • Lower length dysmetria that cannot be mitigated with a wedge under the foot.
  • Skin lesion on parts of the lower extremities that are in contact with the device.
  • History of fracture without trauma.
  • Presence of other conditions causing exercise intolerance (such as uncontrolled hypertension, coronary artery disease, arrhythmia, congestive heart failure, severe pulmonary disease).
  • Conductual disorders that may interfere with the use of the device or their participation in the study, like impulsiveness.
  • Allergy to any of the EXPLORER materials: cotton, nylon, polyester, PPS, PEEK or ABS.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: EXPLORER

Two-week period with the robotics gait device for use in the natural settings deemed appropriate by the family.

Two-week period with the robotics gait device for use in the natural settings deemed appropriate by the family.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Serious Adverse Events
Délai: through study completion, along 2 weeks

occurrence of any serious adverse event to the participant or the caregiver

through study completion, along 2 weeks
Falls prevalence
Délai: through study completion, along 2 weeks

Number of falling events occurred from the participant or caregiver

through study completion, along 2 weeks
Skin integrity
Délai: through study completion, along 2 weeks

Occurrence of any injury of the skin in the areas of contact and produced by the use of the device

through study completion, along 2 weeks
Pain (Visual Analogic Scale)
Délai: through study completion, along 2 weeks

pain measured by the Visual Analogic Scale (VAS) by the participant and the caregiver, scored from 0 to 10, being 0 "no pain" and 10 "unbearable pain"

through study completion, along 2 weeks
Donning and doffing time
Délai: through study completion, along 2 weeks

Time to don and doff the device to each participant

through study completion, along 2 weeks
Device usage time
Délai: through study completion, along 2 weeks

Time using the device

through study completion, along 2 weeks
Number of steps
Délai: through study completion, along 2 weeks

number of steps with the device

through study completion, along 2 weeks
Usage modes
Délai: through study completion, along 2 weeks

two different usage modes (active and automatic).

through study completion, along 2 weeks
Speed
Délai: through study completion, along 2 weeks

speed achieved with the device (steps per minute)

through study completion, along 2 weeks
Device accessibility
Délai: through study completion, along 2 weeks

Environments where the device has been used and level of accessibility in each environment measured with a 5 points Likert scale (0 not accessible - 5 very accessible)

through study completion, along 2 weeks
Range of motion
Délai: Before starting the intervention (S1) and after completing the two weeks of use

Passive Degree to which a joint can move (hip, knee, and ankle joints in both legs). From 0º to 180º.

Before starting the intervention (S1) and after completing the two weeks of use
Participation
Délai: Before starting the intervention (S1) and after completing the two weeks of use

Measured with the Child and Adolescent Scale of Participation. 20 ordinal scaled items across 4 subsections.

Maximum total score is 80 (20 items x 4) and the minimum total score is 20 (20 items x 1)

Before starting the intervention (S1) and after completing the two weeks of use

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
QUEST
Délai: at the end of the intervention

Using the Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0) questionnaire administered to the participants' caregivers at the end of the intervention. The QUEST 2.0 scale has 12 items. Each item is rated on a 5-point Likert scale

at the end of the intervention

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 mars 2025

Achèvement primaire (Réel)

1 août 2026

Achèvement de l'étude (Réel)

1 septembre 2026

Dates d'inscription aux études

Première soumission

20 décembre 2024

Première soumission répondant aux critères de contrôle qualité

2 janvier 2025

Première publication (Réel)

9 janvier 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

16 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

13 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner